DEXCOM INC (DXCM) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$86.11

From 52W high−7.14%

Volume2.56M

Market cap$32.36B

P/E (TTM)33.1x

P/S (TTM)6.5x

Div yield—

Key dataOct 19, 2026

Open

$86.11

From 52W high

−7.14%

Volume

2.56M

Market cap

$32.36B

ValuationView details →

P/E (Fwd)

29.2x

EV/EBITDA

20.4x

P/E (TTM)

33.1x

RSI (14)

49.0

MomentumView details →

1D Return

−0.34%

YTD Return

+28.96%

SummaryUpdated Jun 1, 2026

DexCom, Inc. (NASDAQ:DXCM) is a San Diego-based medical device company founded in 1999 that specializes in continuous glucose monitoring (CGM) systems for diabetes management. The company went public in 2005 and has grown to become a leading player in the diabetes technology market, serving approximately 2.8 million customers globally as of 2024. DexCom has evolved from a specialized medical device manufacturer to a comprehensive diabetes management platform, expanding its reach from traditional insulin-dependent patients to broader diabetes populations and even pre-diabetic individuals through its over-the-counter product offerings.

Ask drillr about DEXCOM INC →

ValuationView details →

P/E (Fwd)

29.2x

P/E (TTM)

33.1x

EV/EBITDA

20.4x

EV/Sales

6.4x

P/S (TTM)

6.5x

P/B (TTM)

12.3x

ProfitabilityView details →

Gross Margin

62.47%

Net Margin

20.12%

EBITDA Margin

31.38%

ROE (TTM)

38.14%

ROA (TTM)

15.49%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

+15.54%

EPS YoY

+76.19%

FCF YoY

+146.15%

Revenue CAGR 3Y

+17.01%

EPS CAGR 3Y

+34.48%

EBITDA YoY

+50.03%

MomentumView details →

1D Return

−0.34%

YTD Return

+28.96%

1Y Return

+25.08%

RSI (14)

49.0

vs 50D SMA

−2.25%

vs 200D SMA

+15.57%

Capital & dividendView details →

Debt/Equity

0.53x

Current Ratio

1.73x

Quick Ratio

1.43x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.70

EPS Surprise

14.38%

Beats (12Q)

9/12

Next Q EPS Est

$0.73

Avg Surprise (4Q)

11.33%

Rev Surprise

1.19%

Financials snapshotView financials →

Revenue (TTM)

4.97B

Net Income (TTM)

999.70M

Op. CF (TTM)

1.75B

Next earningsOct 29, 2026 →

Latest newsMore news →

Dexcom launched the fifth season of Dexcom U, its NIL program for college athletes with diabetes, with a record roster of 27 athletes across 13 sports.13d ago

DexCom, Inc. promoted Jereme Sylvain to EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.35d ago

Similar companies

惠泰医疗688617.SH Koninklijke Philips N.V.PHG Shanghai MicroPort MedBot (Group) Co., Ltd.02252.HK STERIS plcSTE Edwards Lifesciences CorporationEW Hangzhou Diagens Biotechnology Co., Ltd.02526.HK Find similar companies →

Latest newsMore news →

Dexcom launched the fifth season of Dexcom U, its NIL program for college athletes with diabetes, with a record roster of 27 athletes across 13 sports.13d ago DexCom, Inc. promoted Jereme Sylvain to EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.35d ago